API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
SGT-610 (patidegib) is a topical gel formulated, small molecule, Hedgehog signaling pathway Inhibitor drug, which is being investigated for the treatment of Gorlin syndrome.
Lead Product(s): Patidegib
Therapeutic Area: Oncology Product Name: SGT-610
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2023
Details:
The Company intends to use the net proceeds from the Offerings to fund the acquisition of SGT-610, the topically-applied patidegib, a new chemical entity hedgehog signaling pathway blocker, for the treatment of Gorlin syndrome.
Lead Product(s): Patidegib
Therapeutic Area: Oncology Product Name: SGT-610
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Raymond James & Associates
Deal Size: $12.8 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 27, 2023
Details:
SGT-610 (patidegib), an Orphan Drug candidate, broadens Sol-Gel’s pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome, if approved by the FDA.
Lead Product(s): Patidegib
Therapeutic Area: Oncology Product Name: SGT-610
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sol-Gel Technologies
Deal Size: $74.7 million Upfront Cash: $4.7 million
Deal Type: Acquisition January 27, 2023
Details:
PellePharm’s patedigib topical gel is an investigational treatment to be used for rare dermatologic conditions. This is the first step in efforts to enable the renewable production of cyclopamine.
Lead Product(s): Patidegib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Phyton Biotech LLC
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2021
Details:
Poster titled "A Phase 1, Single-center, Pharmacokinetic, Safety and Tolerability Study of Patidegib Topical Gel in Healthy Adult Volunteers Under Maximum Use Conditions" including other studies will be presented at the conference.
Lead Product(s): Patidegib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
PellePharm announced it has dosed the first two participants in a Phase 2 clinical trial of Patidegib Topical Gel, 2%, vs. vehicle gel for people with non-Gorlin High Frequency Basal Cell Carcinoma.
Lead Product(s): Patidegib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2020